Clinical Trial Update: Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis [Phase 3]

View source ↗

Summary

Open-label extension study of reslizumab in pediatric eosinophilic esophagitis completed. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• CINQAIR (Reslizumab)

Snippet

Sponsor: Ception Therapeutics | Conditions: Eosinophilic Esophagitis | Phase 3 | Status: COMPLETED | Results posted: 2017-03-23